Rhythm Pharmaceuticals Surges on Positive Phase 2 Trial Results

Rhythm Pharmaceuticals shares are trading higher after the company announced that its oral MC4R agonist, Bivamelagon, achieved statistically significant and clinically meaningful BMI reductions in a Phase 2 trial for acquired hypothalamic obesity.